A recent study from the NIH Common Fund SenNet program sheds light on the molecular mechanisms underlying lower urinary tract dysfunction (LUTD) in aging, particularly focusing on the sex bias that disproportionately affects women. Researchers investigated the therapeutic potential of a senolytic drug combination—Dasatinib and Quercetin (D&Q)—in aged (25-month-old) Diversity Outbred mice. The study revealed significant baseline sex differences in the expression of unfolded protein response (UPR) and ER-associated degradation (ERAD) proteins, with females exhibiting higher levels of PERK pathway components, indicating a distinct vulnerability in their bladder health.

The findings underscore the importance of cellular senescence and oxidative stress in bladder aging, with D&Q treatment selectively enhancing ERAD markers in females. Notably, D&Q treatment improved uroplakin expression and increased urothelial thickness in aged females, suggesting a potential strategy to bolster urothelial integrity and mitigate LUTD symptoms. This study not only highlights the sex-specific regulatory mechanisms within the UPR pathway but also emphasizes the need for tailored therapeutic approaches in addressing LUTD in aging populations.

The implications of this research are significant for future drug development and aging biology. By elucidating the distinct cellular responses in male and female bladders, this work may shift current research paradigms towards more sex-specific interventions in LUTD. Understanding these mechanisms could accelerate the identification of targeted therapies, ultimately improving healthspan and quality of life for aging individuals, particularly women who are more susceptible to bladder dysfunction.

Source: academic.oup.com